Document is current
Any future updates will be listed below
-
Authors
Paskins, Z. https://orcid.org/0000-0002-7783-2986
Babatunde, O.
Sturrock, A.
Toh, L. S.
Horne, R.
Maidment, I.
,
McCloskey, Eugene
Paskins, Zoe
Armstrong, David
Curtis, Elizabeth
Edwards, John
Javaid, Kassim
Hill, Thomas
O’Neill, Terry
Stone, Michael
Walsh, Jennifer
McKinley, Janice
Turnbull, Corinne
Compston, Juliet
Harvey, Nick
Reid, David
Vine, Nic
Bishop, Mary
-
Funding
Funding for this research was provided by:
National Osteoporosis Society
- License Information
-
More Information
Article History
Received: 18 February 2022
Accepted: 28 May 2022
First Online: 11 June 2022
Declarations
:
: RH reports speaker engagements with honoraria with the following companies: AbbVie, Abbott, Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Biogen, Gilead Sciences, GlaxoSmithKline, Janssen, Merck Sharp Dohme, Merck, Novartis, Pfizer, Procter & Gamble, Roche, Sanofi, Shire Pharmaceuticals, TEVA, UCB. RH is Founding Director of a UCL-Business company (Spoonful of Sugar Ltd) providing consultancy on treatment engagement and patient support programmes to healthcare policy makers, providers, and pharmaceutical industry. ZP reports unpaid consultancy for UCB Pharma. OB, AS, LST, and IM report no conflicts of interest. Also, Professor Rob Horne is supported by the National Institute for Health and Care Research (NIHR, Applied Research Collaboration (ARC)), North Thames at Bart’s Health NHS Trust and Asthma UK (AUKCAR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.
